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Abstract
We have recently identified a novel population of activated low-density granulocytes (LDGs) in peripheral blood
mononuclear cells of HIV seropositive patients. LDGs have a similar morphology to normal density granulocytes (NDGs), but
are phenotypically different. Here we measured the expression levels of different phenotypic markers of granulocytes in the
blood of HIV seropositive patients at different stages of HIV infection to determine whether the phenotype of NDGs and
LDGs are affected by disease severity. Our results reveal that the phenotype of NDGs, but not that of LDGs, varies according
to the severity of the disease.
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Introduction
Neutrophils play a central role in the elimination of pathogens
by using several strategies such as the production of reactive
oxygen species, the release of antimicrobial peptides and
neutrophil extracellular traps (NETs) (summarised in [1]). In
HIV infections, both the number and the functions of neutrophils
are impaired (summarised in [2]). Functional abnormalities of
neutrophils include impaired phagocytosis and production of toxic
oxygen species [2]. Furthermore, it has been recently shown that
whereas NETs formation can capture and eliminate HIV, HIV
can counteract this by inducing the production of IL-10 by
dendritic cells and therefore inhibiting NETs formation [3].
Human neutrophils constitutively express arginase [4], an
enzyme that catalyses the conversion of L-arginine into ornithine
and urea [5,6]. Recently, the metabolism of L-arginine by arginase
has emerged as a crucial mechanism for the regulation of immune
responses: increased catabolism of L-arginine by arginase results in
the depletion of L-arginine from the microenvironment; since L-
arginine is essential for efficient T cell activation, this decrease in
L-arginine results in impaired T cell responses [7,8,9,10].
Increased arginase activity has been described in malaria [11],
tuberculosis [12], leishmaniasis [13,14,15] and HIV [16,17].
We have recently shown that PBMCs from HIV seropositive
patients with low CD4+ T cell counts expressed significantly more
arginase activity as compared to patients with high CD4+ T cell
counts or uninfected controls [16]. Higher arginase expression in
PBMCs from HIV seropositive patients was associated with
decreased levels of CD3f expression, a marker of T cell
dysregulation [16]. The phenotype of arginase-expressing cells
was identified as low-density granulocytes (LDGs) as these cells co-
purify with PBMCs following density gradient centrifugation. This
difference in density distinguishes this population from the
remaining granulocytes that co-purify with the erythocyte fraction
following density gradient centrifugation and thus have been
named normal-density granulocytes (NDGs). LDGs purified from
HIV+ patients display a similar morphology as NDGs, but have
major phenotypic differences suggesting that LDGs were activated
neutrophils that had degranulated and released arginase [17]. In
the present study, we aim to determine whether the phenotype of
NDGs and LDGs differs in different stages of HIV infection.
Materials and Methods
Subjects and samples
Twenty-one HIV seropositive (HIV+) treatment-naı¨ve individ-
uals were recruited from St Mary’s Hospital (Table 1). Plasma
HIV-1 viral RNA was quantified by real-time PCR (Bayer
Quantiplex assay (bDNA) PCR test; lower detection level of 50
copies/mL). The standard T lymphocyte markers CD3, CD4,
CD8 were determined by flow cytometry. The study was approved
by the National Research Ethics Service (05/Q0410/93) and all
individuals gave written, informed consent before participation.
Twenty ml of peripheral blood was collected in EDTA tubes
and PBMCs were isolated by density gradient centrifugation on
HistopaqueH-1077 (Sigma). Neutrophils were isolated from the
erythrocyte fraction by dextran sulphate sedimentation [17]. All
experiments were performed on fresh cell, immediately after
processing.
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Flow cytometry
The following antibodies were used: CD14FITC, CD15PE (BD
Pharmingen), Arginase1Alexa FluorH647 (Hycult Biotechnology),
CD11bPerCP-eFluro710, CD16eFluro450, CD33PE-Cy7 (eBioscience),
CD13APC-Cy7 (Biolegend), CD66bFITC and CD63FITC (Beckman
Coulter). 16106 PBMCs were incubated with FcR blocking
reagent (BD Pharmingen) and the antibodies against extracellular
markers were added directly to cells. Cells were washed after
20 min, fixed, permeabilised and anti-arginase IAlexa FluorR 647 was
added to the cells for 20 min as described in [18]. Analysis was
performed on an FACS Canto II (BD Bioscience) and results were
analyzed using FlowJo v8.7 (Tree Star, Ashland, OR).
Statistical analyses
Data were evaluated for statistical differences using a two-tailed
Mann-Whitney test and a Spearman’s rank test when appropriate
(GraphPad Prism 5); differences were considered statistically
significant at p,0.05. Results are expressed as median6 SEM.
Results
We first analysed the phenotype of NDGs to determine whether
it changes with increased disease severity, as measured by CD4+ T
cell counts and viral load. We measured the expression levels of
CD11b, CD13, CD15, CD16, CD33, CD63, CD66b and arginase
on NDGs from treatment naı¨ve HIV+ patients with high ($350
cells/mL, CD4high) and low (,350 cells/mL, CD4low) CD4+ T
cell counts. The division of patients based on a CD4+ T cell count
,350 cells/mL was chosen because 1) once the CD4+ T cell count
falls below 350 cells/mL differences in clinical outcome increas-
ingly appear [19] and 2) the initiation of antiretroviral therapy is
recommended once CD4+ T cell count falls to,350 cells/mL [20].
Our results show that the MFIs of CD13 and arginase are
statistically significantly lower (p=0.0008 and p=0.0048, respec-
tively) and that of CD63 significantly higher (p=0.0346) in the
blood of CD4low HIV+ patients (Figure 1, Table 2) as compared
to CD4high HIV+ patients. No significant difference was observed
in the expression levels of CD11b (p=0.9159), CD15 (p=0.3072),
CD16 (p=0.5495), CD33 (p=0.3787) and CD66b (p=0.6985)
between CD4high and CD4low HIV+ patients (Table 2). Of note,
the expression levels of CD11b, CD13, CD15, CD16, CD33,
CD63, CD66b and arginase 1 were homogenous (Figure S1).
To characterise further the association between these markers
and disease severity, we plotted their MFI values against CD4+ T
cell counts. As shown in Figure 2, there are statistically significant
positive correlations between CD4+ T cell counts and the MFIs of
CD13 (p=0.0007), arginase (p=0.0196) and CD16 (p=0.0400);
and a significant negative correlation between CD4+ T cell counts
and the MFI of CD63 (p=0.0097) (Figure 2, Table 3). No
significant correlation was observed between CD4+ T cell counts
and CD11b (p=0.5122), CD15 (p=0.0580), CD33 (p=0.0825),
and CD66b (p=0.6064) (Table 3).
Next, we plotted expression levels of CD11b, CD13, CD15,
CD16, CD33, CD63, CD66b and arginase against another
marker of disease severity, viral load. A statistically significant
negative correlation between VL and arginase (p=0.0063,
Figure 3) and a trend towards significance between VL and
CD13 (p=0.0553, Table 4) were observed, all other correlations
were not statistically significant (Figure 3, Table 4).
These results suggest that in HIV+ patients, the phenotype of
NDGs varies according to the severity of the disease.
Our previous results have identified a novel population of low-
density granulocytes (LDGs) in the PBMCs of HIV+ patients that
are morphologically similar, but phenotypically different from
NDGs. Here, we determined whether the MFIs value differ in this
population of LDGs and whether there was a correlation between
markers of disease severity and the expression levels of CD11b,
CD13, CD15, CD16, CD33, CD63, CD66b and arginase: MFIs
values were similar between LDGs from CD4low and CD4high
HIV+ patients (Table 5) and none of the correlations were
statistically significant (Tables 6 and 7).
These results suggest that the phenotype of NDGs, but not that
of LDGs varies according to the severity of the disease.
Phenotype of NDGs and LDGs in CD4low HIV+ patients
We have previously shown that LDGs are phenotypically
different from NDGs, as they express increased levels of CD11b,
CD15, CD33, CD66b, CD63 and decreased levels of CD16 and
arginase 1 [17], suggesting that these cells are activated neutrophils
that have degranulated and therefore change their density. Indeed,
the results presented in Figure 2 suggest that NDGs get
progressively more activated with increased disease severity, as
measured by CD4+ T cell counts. In the next step, we assessed
how the phenotype of NDGs differs from that of LDGs in
CD4high and CD4low HIV+ patients. As shown in Figure 4 and
Tables 8 and 9, the expression levels of CD16, arginase and CD63
are significantly different between LDGs and NDGs from
CD4high HIV+ patients, but are similar in CD4low patients.
Differences between CD11b, CD13 and CD66b MFIs remain
non-significant and differences between CD15 and CD33 remain
significant in CD4low and CD4high HIV+ groups.
Table 1. Clinical data.
Patients Age Sex (M/F) CD4 count Viral load
1 46 M 840 3.42
2 38 M 780 4.96
3 33 M 680 4.35
4 41 M 620 3.25
5 27 M 580 2.39
6 60 M 540 3.16
7 42 M 540 4.54
8 34 M 540 4.77
9 23 M 520 3.99
10 30 F 440 4.24
11 46 M 390 5.27
12 48 M 330 4.79
13 51 M 300 5.57
14 40 M 170 4.91
15 34 M 160 4.6
16 49 M 160 4.4
17 46 M 140 5.28
18 38 M 128 5.69
19 27 F 25 5.57
20 44 M 20 5.7
21 38 F 4 4.43
Age, sex, CD4+ T cell counts and viral load were recorded for HIV+ patients
(n = 21).
doi:10.1371/journal.pone.0072034.t001
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Discussion
We have previously shown that arginase activity was signifi-
cantly increased in the blood of CD4low HIV+ patients as
compared to CD4high and healthy controls [16]. The phenotype
of arginase-expressing cells in the PBMCs of HIV+ patients are a
subset neutrophils, which were classified as low-density granulo-
cytes (LDGs) [16,17]. These cells have a similar morphology as
normal density granulocytes (NDGs) [17]. However, LDGs differ
from NDGs as i) they co-localise with the PBMCs and not the
erythrocytic fractions, suggesting that their density is lower; ii) they
express different levels of phenotypic markers of neutrophils. In
addition, our results show that the frequency of LDGs is
significantly higher in HIV+ patients with low CD4+ T cell counts
and correlates with markers of disease severity in HIV+ patients
[17]. We have already shown that the cells expressing arginase in
PBMCs from HIV+ patients are LDGs, as they express CD15, but
not CD14, and that the frequency of these cells increases with
disease severity [16].
Our results show that there is no difference between the
phenotype of LDGs from CD4low and CD4high HIV+ patients;
however, there are clear phenotypic differences in the expression
levels of CD13, CD63 and arginase in NDGs from HIV+ patients
with low CD4+ T cell counts. Increased activation of neutrophils
in HIV+ patients has already been described [21]. In this study,
the expression levels of CD11b were shown to be increased on
neutrophils from HIV+ patients as compared to HIV- controls. In
our study we assessed whether the level of neutrophils’ activation
changes with disease severity, rather then comparing it to healthy
controls. Our results are in agreement with the study by Elbim et
al., as we did not find a change in CD11b expression on NDGs
with lower CD4+ T cell counts.
Our results suggest that during the course of HIV infection,
there is no progressive activation of LDGs, as we found no
correlation between CD4+ T cell counts or viral load and the
Figure 1. Phenotypic analysis of NDGs. NDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts.350 (n = 11) or,350 cells/
mL (n = 10) as described in materials and methods and the expression levels of phenotypic markers were determined by flow cytometry. Isotype
controls: ,1%. Statistical significance was determined by a two-tailed Mann-Whitney test. Box = interquartile range and median; whiskers = range.
doi:10.1371/journal.pone.0072034.g001
Table 2. Phenotype of NDGs.
CD4high CD4low p value
(median ± SEM) (median ± SEM)
CD11b 26846767 34186610 0.9159
CD13 39156345 20916152 0.0008
CD15 22706693 37326812 0.3072
CD16 102596934 87316743 0.5495
CD33 21146196 16446241 0.3787
CD63 751657 10356152 0.0346
CD66b 63266771 68546604 0.6985
arginase 22946148 19046124 0.0448
NDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and expression levels of phenotypic markers were determined by flow
cytometry.
doi:10.1371/journal.pone.0072034.t002
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expression levels of CD11b, CD13, CD15, CD16, CD33, CD63,
CD66b and arginase 1. However, our results suggest that NDGs
become progressively and systemically more activated and more
degranulated, since decreased expression levels of CD13, CD16
and arginase and increasing expression levels of CD63 on NDGs
correlate with decreasing CD4+ T cell counts. The degree of
neutrophil activation is regulated by the intensity of the activating
signal and occurs sequentially: 1) secretory granules; 2) gelatinous
granules; 3) specific and 4) azurophilic granules. Arginase is found
Figure 2. Correlation between CD4+ T cells and phenotypic markers. NDGs were isolated from the blood of HIV+ patients (n = 21) as
described in materials and methods and the expression levels of phenotypic markers were determined by flow cytometry. Correlation between CD4+
T cell counts and phenotypic markers was determined by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.g002
Table 3. NDGs: Correlation between CD4+ T cell counts and
MFIs.
Spearman r p value
CD11b 20.1522 0.5122
CD13 0.6797 0.0007
CD15 20.3707 0.0980
CD16 0.4514 0.0400
CD33 0.3876 0.0825
CD63 20.5504 0.0097
CD66b 20.1213 0.6034
arginase 0.5047 0.0196
NDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and the correlations between CD4+ T cell counts and phenotypic
markers were determined by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.t003
Figure 3. Correlation between viral load and phenotypic
markers. NDGs were isolated from the blood of HIV+ patients
(n = 21) as described in materials and methods and the expression
levels of phenotypic markers were determined by flow cytometry.
Correlation between viral load and phenotypic markers was determined
by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.g003
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in gelatinous granules [22] and azurophilic granules [4] and
upregulation of CD63 on neutrophils coincides with the release of
azurophilic granule [23,24]. Therefore, our result showing that
CD63 is expressed at increased levels and arginase at lower levels
in NDGs from patients with low CD4+ T cells suggest that NDGs
get progressively more activated with increased disease severity.
We hypothesise that as a result of degranulation, NDGs will
change their density and become LDGs, and will be collected in
the PBMC fraction following density gradient purification. Our
results suggest that NDGs are activated and have already, at least
partially, released azurophilic granules, as shown by increased
CD63 and decreased arginase expression levels in CD4low HIV+
patients. Furthermore, our results show that the MFIs of CD16,
CD63 and arginase are significantly different between LDGs and
NDGs in CD4high HIV+ patients, but not any more in CD4low
HIV patients; suggesting that there are less differences between the
phenotype of LDGS and NDGs in CD4low as compared to
CD4high HIV+ patients.
The origins of LDGs as well as the signals resulting in the
degranulation of neutrophils remain unclear in HIV+ patients and
we have not been able to activate NDGs to become LDGs.
Stimulation of neutrophils with Phorbol 12-myristate 13-acetate
Table 4. NDGs: Correlation between viral loads and MFIs.
Spearman r p value
CD11b 0.1104 0.6337
CD13 20.4242 0.0553
CD15 0.1241 0.5921
CD16 20.2014 0.3814
CD33 20.1845 0.4234
CD63 0.1358 0.5572
CD66b 0.1358 0.5574
arginase 20.5762 0.0063
NDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and thes correlation between viral load and phenotypic markers were
determined by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.t004
Table 5. Phenotype of LDGs.
CD4high CD4low p value
(median ± SEM) (median ± SEM)
CD11b 44136649 51486890 0.2907
CD13 21376564 23686366 0.9159
CD15 1001261277 82626769 0.3072
CD16 152861483 693261112 0.5035
CD33 35756285 27686304 0.1300
CD63 14746178 13556246 0.9717
CD66b 889962404 1019861775 0.6472
arginase 17006141 15336123 0.2453
LDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and the expression levels of phenotypic markers were determined by
flow cytometry.
doi:10.1371/journal.pone.0072034.t005
Table 6. LDGs: Correlation between CD4+ T cell counts and
MFIs.
Spearman r p value
CD11b 20.3507 0.1191
CD13 0.1028 0.6576
CD15 0.1502 0.5157
CD16 0.0072 0.9754
CD33 0.4039 0.0694
CD63 0.1158 0.6173
CD66b 20.0134 0.9531
arginase 0.2738 0.7009
LDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and the correlations between CD4+ T cell counts and phenotypic
markers were determined by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.t006
Table 7. Correlation between viral loads and MFIs.
Spearman r p value
CD11b 0.2242 0.3286
CD13 0.0071 0.9755
CD15 20.2007 0.3830
CD16 20.0084 0.9710
CD33 20.3248 0.1509
CD63 20.0364 0.8756
CD66b 0.0948 0.6826
arginase 20.4722 0.2235
LDGs were isolated from the blood of HIV+ patients with CD4+ T cell counts
.350 cells/mL (n = 11) or ,350 cells/mL (n = 10) as described in materials and
methods and the correlations between viral load and phenotypic markers were
determined by a Spearman’s rank test.
doi:10.1371/journal.pone.0072034.t007
Table 8. LDGs and NDGs in HIV+ patients in CD4low HIV+
patients.
LDGs NDGs p value
(median ± SEM) (median ± SEM)
CD11b 51486890 34186610 0.2176
CD13 23686366 20916152 0.9705
CD15 82626769 37326812 0.0015
CD16 693261112 87316743 0.0630
CD33 27686304 16446241 0.0288
CD63 13556246 10356152 0.1230
CD66b 1019861775 76716604 0.0355
arginase 15336123 19046124 0.0630
LDGs and NDGs were isolated from the blood of HIV+ patients with CD4+ T cell
counts,350 cells/mL (n = 10) as described in materials and methods. Expression
levels of phenotypic markers were determined by flow cytometry.
doi:10.1371/journal.pone.0072034.t008
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(PMA) and/or N-formyl-methionyl-leucyl-phenylalanine (fLMP)
has been described previously ([23]: whereas these stimuli result in
activation and degranulation of neutrophils, the phenotype of
these activated neutrophils differs from that of LDGs we described
[17], as CD13 and CD16 are both downregulated on activated
NDGs.
Further work into novel markers of immune suppression, such
as activation of granulocytic cells, is warranted as this may result in
improvement in the clinical management of patients with HIV
infection through: 1) better evaluation of disease severity (including
the stage and rate of progression of the disease) and 2) informing
the timing and choice of treatment initiation so as to minimise
morbidity associated with opportunistic infections, drug resistance
and medication side effects.
Supporting Information
Figure S1 Phenotypic analysis of NDGs. NDGs were
isolated from the blood of HIV+ patients with CD4+ T cell
counts .350 (n= 11) or ,350 cells/mL (n= 10) as described in
materials and methods and the expression levels of phenotypic
markers were determined by flow cytometry. Isotype controls:
,1%. Statistical significance was determined by a two-tailed
Mann-Whitney test. Box= interquartile range and median;
whiskers = range.
(TIF)
Figure 4. Phenotypes of NDGs and LDGs in CD4low and CD4high HIV+ patients. PBMCs and NDGs were isolated from the blood of HIV+
patients with CD4+ T cell counts .350 (n = 11) or ,350 cells/mL (n = 10) as described in materials and methods and the expression levels of
phenotypic markers were determined by flow cytometry. Isotype controls: ,1%. Statistical significance was determined by a two-tailed Mann-
Whitney test. Box = interquartile range and median; whiskers = range.
doi:10.1371/journal.pone.0072034.g004
Table 9. LDGs and NDGs in HIV+ patients in CD4high HIV+
patients.
LDGs NDGs p value
(median ± SEM) (median ± SEM)
CD11b 44136694 26846767 0.5994
CD13 21376564 39156345 0.1007
CD15 1001261277 22706693 0.0003
CD16 152861483 102596934 0.0216
CD33 35756285 21146196 0.0016
CD63 14746178 751657 0.0001
CD66b 889961775 76976604 0.1679
arginase 17006141 22946150 0.0126
Ldgs And Ndgs Were Isolated From The Blood Of Hiv+ Patients With Cd4+ T Cell
Counts .350 Cells/mL (N = 11) As Described In Materials And Methods.
Expression Levels Of Phenotypic Markers Were Determined By Flow Cytometry.
doi:10.1371/journal.pone.0072034.t009
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